Personal information

China

Activities

Employment (3)

Central South University: Changsha, Hunan, CN

2017-09 to present | Professor (Department of Medicinal Chemistry)
Employment
Source: Self-asserted source
Qianbin Li

Central South University: Changsha, Hunan, CN

2010-04 to 2017-09 | Associate professor (Department of Medicinal Chemistry)
Employment
Source: Self-asserted source
Qianbin Li

Virginia Commonwealth University: Richmond, VA, US

2008-02 to 2010-03 | Postdoc (Department of Medicinal Chemistry)
Employment
Source: Self-asserted source
Qianbin Li

Education and qualifications (2)

Shandong University: Jinan, Shandong, CN

2003-09-01 to 2008-12-31 | Doctor (Department of Medicinal Chemistry)
Education
Source: Self-asserted source
Qianbin Li

Shandong University: Jinan, Shandong, CN

1999-09-01 to 2003-06-30 | Bachelor
Education
Source: Self-asserted source
Qianbin Li

Works (30)

Carrier Polymer-Free Dissolvable Microneedles Enable Superhigh Drug Payload for Percutaneous Protein Delivery

ACS Materials Letters
2024-11-04 | Journal article
Contributors: Zhao Wang; Lin Liu; Ergang Liu; Rongli Chen; Yongzhuo Huang; Qianbin Li
Source: check_circle
Crossref

Virtual Screening, Molecular Dynamics, and Mechanism Study of Homeodomain-Interacting Protein Kinase 2 Inhibitor in Renal Fibroblasts

Pharmaceuticals
2024-10-23 | Journal article
Contributors: Xinlan Hu; Yan Wu; Hanyi Ouyang; Jiayan Wu; Mengmeng Yao; Zhuo Chen; Qianbin Li
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Discovery and Optimization of Hsp110 and sGC Dual-Target Regulators for the Treatment of Pulmonary Arterial Hypertension

Journal of Medicinal Chemistry
2024-08-08 | Journal article
Contributors: Yuanbo Hu; Congke Zhao; Wenhua Tan; Mengqi Li; Yu Wang; Ruizhe Gao; Zhuo Chen; Zhenming Jin; Liqing Hu; Qianbin Li
Source: check_circle
Crossref

Recent Advances in the Development of HIPK2 Inhibitors As anti-renal Fibrosis Agents

Future Medicinal Chemistry
2023-03 | Journal article
Contributors: Chao Hao; Meng Cao; Hanyi Ouyang; Zhuo Chen; Gaoyun Hu; Qianbin Li
Source: check_circle
Crossref

Novel pyrazolo[3,4‐b]pyridine derivatives: Synthesis, structure–activity relationship studies, and regulation of the AMPK/70S6K pathway

Archiv der Pharmazie
2022-07 | Journal article
Contributors: Yating Guo; Xiaoding Jiang; Qi Chang; Zhihong Xiao; Zhuo Chen; Dejian Jiang; Gaoyun Hu; Qianbin Li
Source: check_circle
Crossref

Multistep virtual screening based identification of homeodomain-interacting protein kinase 2 inhibitors: An opportunity for treating Chronic Kidney Disease

Chemometrics and Intelligent Laboratory Systems
2021-12 | Journal article
Contributors: Yuanyuan Cao; Xiangyang Le; Xiaomei Shi; Chao Hao; Binghao Ma; Zhuo Chen; Gaoyun Hu; Dongsheng Cao; Qianbin Li
Source: check_circle
Crossref

Discovery of Novel Pyrazolo[3,4-b] Pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension

Journal of Medicinal Chemistry
2020-10-08 | Journal article
Contributors: Liqing Hu; Lijun Li; Qi Chang; Songsen Fu; Jia Qin; Zhuo Chen; Xiaohui Li; Qinglian Liu; Gaoyun Hu; Qianbin Li
Source: check_circle
Crossref

Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents

Bioorganic & Medicinal Chemistry
2020-05 | Journal article
Contributors: Qi Chang; Jing Long; Liqing Hu; Zhuo Chen; Qianbin Li; Gaoyun Hu
Source: check_circle
Crossref

Discovery of a Dual Tubulin Polymerization and Cell Division Cycle 20 Homologue Inhibitor via Structural Modification on Apcin

Journal of Medicinal Chemistry
2020-05-14 | Journal article
Contributors: Pan Huang; Xiangyang Le; Fei Huang; Jie Yang; Haofeng Yang; Junlong Ma; Gaoyun Hu; Qianbin Li; Zhuo Chen
Source: check_circle
Crossref

Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors.

Bioorganic & medicinal chemistry
2019-03-22 | Journal article
Source: Self-asserted source
Qianbin Li

Dual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design, synthesis and preliminary anticancer activity studies of 3-substituted-5-(phenylamino) indolone derivatives.

Bioorganic & medicinal chemistry
2019-01 | Journal article
Contributors: Yu Z; Chen Z; Su Q; Ye S; Yuan H; Kuai M; Lv M; Tu Z; Yang X; Liu R et al.
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.

Bioorganic & medicinal chemistry letters
2017-07 | Journal article
Contributors: Chen J; Peng Z; Lu M; Xiong X; Chen Z; Li Q; Cheng Z; Jiang D; Tao L; Hu G
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Soluble Guanylate Cyclase: A New Therapeutic Target for Fibrotic Diseases.

Current medicinal chemistry
2017-01 | Journal article
Contributors: Hu L; Wang Z; Yi R; Yi H; Xiao S; Chen Z; Hu G; Li Q
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol.

Current medicinal chemistry
2016-01 | Journal article
Contributors: Zhu W; Chen Z; Li Q; Tan G; Hu G
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.

Future medicinal chemistry
2015-01 | Journal article
Contributors: Yu Z; Ye S; Hu G; Lv M; Tu Z; Zhou K; Li Q
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives.

Drug discovery today
2014-10 | Journal article
Contributors: Lv M; Chen Z; Hu G; Li Q
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Synthesis, pharmacophores, and mechanism study of pyridin-2(1H)-one derivatives as regulators of translation initiation factor 3A.

Archiv der Pharmazie
2013-08 | Journal article
Contributors: Zhu W; Shen J; Li Q; Pei Q; Chen J; Chen Z; Liu Z; Hu G
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Design, synthesis and anti-fibrosis activity study of N₁-substituted phenylhydroquinolinone derivatives.

Molecules (Basel, Switzerland)
2012-02 | Journal article
Contributors: Wu L; Liu B; Li Q; Chen J; Tao L; Hu G
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Synthesis, pharmacokinetics, and pharmacodynamics studies of valsartan peptide derivatives.

Archiv der Pharmazie
2012-01 | Journal article
Contributors: Wu C; Hu Y; Li Q; He L; Chen J; Cheng Z; Li Y; Hu G
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Novel potent 2,5-pyrrolidinedione peptidomimetics as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.

Bioorganic & medicinal chemistry letters
2011-12 | Journal article
Contributors: Li Q; Fang H; Wang X; Hu G; Wang Q; Xu W
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization.

European journal of medicinal chemistry
2011-10 | Journal article
Contributors: Liu K; Rao W; Parikh H; Li Q; Guo TL; Grant S; Kellogg GE; Zhang S
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways.

Bioorganic & medicinal chemistry letters
2010-06 | Journal article
Contributors: Li Q; Wu J; Zheng H; Liu K; Guo TL; Liu Y; Eblen ST; Grant S; Zhang S
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Novel aminopeptidase N (APN/CD13) inhibitors derived from 3-phenylalanyl-N'-substituted-2,6-piperidinedione.

Bioorganic & medicinal chemistry
2010-06 | Journal article
Contributors: Zhang X; Fang H; Zhu H; Wang X; Zhang L; Li M; Li Q; Yuan Y; Xu W
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Structure-based design, chemistry and activity evaluation. II.

European journal of medicinal chemistry
2010-01 | Journal article
Contributors: Li Q; Fang H; Wang X; Xu W
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors.

Bioorganic & medicinal chemistry letters
2009-09 | Journal article
Contributors: Li Q; Al-Ayoubi A; Guo T; Zheng H; Sarkar A; Nguyen T; Eblen ST; Grant S; Kellogg GE; Zhang S
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Design, chemistry and activity evaluation. Part I.

European journal of medicinal chemistry
2009-07 | Journal article
Contributors: Li Q; Fang H; Wang X; Hu L; Xu W
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Alpha-amido acyl-ring imide peptoid metalloprotease inhibitor and application thereof

2009-04 | Patent
OTHER-ID:

CN101538311

Contributors: WENFANG XU; QIANBIN LI; XUEJIAN WANG; HAO FANG
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Novel 3-galloylamido-N'-substituted-2,6-piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors.

Bioorganic & medicinal chemistry letters
2007-01 | Journal article
Contributors: Li Q; Fang H; Xu W
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Progress in the development of aminopeptidase N (APN/CD13) inhibitors.

Current medicinal chemistry. Anti-cancer agents
2005-05 | Journal article
Contributors: Xu W; Li Q
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Novel anticancer targets and drug discovery in post genomic age.

Current medicinal chemistry. Anti-cancer agents
2005-01 | Journal article
Contributors: Li Q; Xu W
Source: Self-asserted source
Qianbin Li via Europe PubMed Central

Peer review (3 reviews for 1 publication/grant)

Review activity for Journal of medicinal chemistry. (3)